Healthcare
Live Price
Offline$0.731
+2.67% today
1Y Change
+28.66%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tenaya Therapeutics, Inc. (TNYA) is a Healthcare stock with a market cap of $120.00M and listed on NASDAQ. The stock last traded around $0.73 and up 28.7% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +55.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +55.0%, free cash flow +24.7% with operating margin 0.0% and ROIC -69.4%. Stock Foundry combines TNYA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNYA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TNYA Max Drawdown
-73.81%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TNYA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$72.7M
+41.2% YoY
Free Cash Flow
-$85.9M
+31.3% YoY
Revenue Growth
+0.0%
EPS Growth
+55.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -8M | -8M | -9M | -9M | -4M |
| Operating Income | -93M | -116M | -131M | -126M | -73M |
| EBITDA | -85M | -103M | -115M | -115M | -69M |
| Net Income | -91M | -111M | -124M | -124M | -73M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 101M | 4M | 46M | 95M | 38M |
| Total Assets | 147M | 120M | 171M | 279M | 317M |
| Total Liabilities | 24M | 27M | 31M | 36M | 38M |
| Shareholder Equity | 123M | 93M | 139M | 243M | 279M |
| Total Debt | 11M | 14M | 12M | 15M | 16M |
| Net Debt | -90M | 9M | -33M | -80M | -22M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
61M
+41.8% YoY
Capital Expenditures
25M
-21.8% YoY
Free Cash Flow
86M
+31.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-85.2%
Debt / Equity
0.09x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.